Non Commercial Use Only

Total Page:16

File Type:pdf, Size:1020Kb

Non Commercial Use Only Neurology International 2016; volume 8:6322 Neuropathic pain treatment: Differently, central NP is infrequent, including pain due to spinal cord injury; pain is multiple Correspondence: Bruno Lima Pessoa, still a challenge sclerosis (MS), post-stroke pain, and etc.2 Neuropathic Pain Division of the Usually, patients with NP can present with Neurology/Neuroscience Clinical Research Osvaldo J.M. Nascimento,1 Bruno L. lancinating, shooting and/or burning pain Subunit of Antonio Pedro University Hospital, Pessoa,1 Marco Orsini,2 Pedro Ribeiro,2 along with tingling sensation. Positive sensory Universidade Federal Fluminense (UFF), RuaSiqueira Campos, 53/1204, Copacabana, Rio Eduardo Davidovich,1 Camila Pupe,1 symptoms such as spontaneous or evoked pain Pedro Moreira Filho,1 de Janeiro, RJ, 22031-071 Brazil. in response to noxious or non-noxious stimuli E-mail: [email protected] Ricardo Menezes Dornas,1 (hyperalgesia and allodynia, respectively) may Lucas Masiero,1 Juliana Bittencourt,2 also occur.3,4 Besides, a well-performed history Key words: Neurology; pain; treatment. Victor Hugo Bastos3 and physical examination are the best tools for 1Neuropathic Pain Division, the correct diagnosis. Electrophysiological Contributions: the authors contributed equally. Neurology/Neuroscience Clinical tests, imaging, and at times histological exam- ination points to the diagnosis, although NP is Conflict of interest: the authors declare no poten- Research Subunit, Antonio Pedro still diagnosed based on clinical aspects.4 tial conflict of interest. University Hospital, Federal Fluminense Initially, the management of NP consists of University, Niterói; 2Brain Mapping Received for publication: 24 November 2015. drug therapy and interdisciplinary approaches. Accepted for publication: 6 June 2016. Department, Federal University of Rio de As the last resource, surgical intervention Janeiro, IPUB, Rio de Janeiro; might be demanded, mainly in patients with This work is licensed under a Creative Commons Department of Medicine, Severino refractory NP.5,6 This review will focus on new Attribution NonCommercial 4.0 License (CC BY- Sombra University, Vassouras, Rio de pharmacological treatments for NP. NC 4.0). Janeiro; 3Piaui Federal University, Physical Therapy School, Brazil ©Copyright O. J.M. Nascimento et al., 2016 Licensee PAGEPress, Italy Pharmacological interventions Neurology International 2016; 8:6322 doi:10.4081/ni.2016.6322only Abstract The pharmacological treatment of NP is based on antidepressant and antiepileptic Neuropathic pain (NP) is the result of a drugs. Still, opioid use can also be considered,useAcetyl-L-carnitine series of conditions caused by diseases or but are commonly regarded controversial. lesions to the somatosensory system. Due to These drugs are well studied and established ALC is an ester produced by the human the better understanding of NP pathophysiolo- in clinical practice, but their estimated pain brain, liver, and kidney. ALC seems to increase gy previously unexplored therapies have been relief is not higher than 40-50%.6 Also, placebo the uptake of Acetyl-CoA into the mitochondria used with encouraging results. In this group, effects may range from 30% bringing uncer- and exerts cholinomimetic effects because it is acetyl-L-carnitine, alpha-lipoic-acid, cannabi- tainty about the effectiveness of these drugs in similar in structure to acetylcholine.12,13 In a noids, clonidine, EMA401, botulinum toxin some patients. We have been observed this controlled randomized trial performed by Sima type A and new voltage-gated sodium channel effect in real life and a daily basis.7 Among the Anders and colleagues,13 ALC was demonstrat- blockers, can be included. Besides, changing new therapeutic options, some studies have ed to be efficacious in reducing NP, as well as paradigms may occur with the advent of opto- been highlighted Acetyl-L-carnitine (ALC), improving nerve fiber regeneration in patients genetics and a better understanding of epige- Alpha-lipoic-acid (ALA), cannabis products, with diabetic neuropathy.13 netic regulation. We reviewed the published botulinumcommercial toxin and angiotensin type 2 recep- Nevertheless, De Grandis and Minardi14 literature on the pharmacological treatment of tor antagonists.6 Additionally, the new voltage- observed similar results in a multicenter, ran- NP. Despite the interesting results, random- gated sodium channel blockers, among which domized, double-blind, placebo-controlled ized controlled trials are demanded the major- we highlight Nav1.7, Nav1.8, Nav1.3, and study including 333 diabetic patients with dia- ity of the therapies previously mentioned. In Nav1.9, are expected to be superior to other betic neuropathy. Randomization occurred to spite of several studies for the relief ofNon NP, pain sodium channel blockers. Since these NAV’s receive either ALC or a placebo. The active control continues being a challenge. are receptor specific, they may lead to less treatment group received 1 g of intramuscular- potential cardiac, motor, and CNS side effects.8 ly ALC for ten days following 2 g of orally ALC In the same way, the use of specific blockers of for 355 days. The ALC group demonstrated a the alpha-2-delta-1 (Cav 2 1) subunit of calci- 39% decrease in pain measured by VAS Introduction um channels has been studied as a potential (P<0.01 vs. baseline) in 12 months; vs. 8% antinociceptive drug, based on the concept of reduction in the placebo group. Significant Neuropathic pain (NP) is a condition due to these channels might be overexpressed in change in nerve conduction velocity was found diseases or lesions affecting the somatosenso- some pain states.9 Till now, there is a lack of in sural nerve (+7 m/sec in ALC vs. +1 m/sec ry nervous system pathways, either in the cen- enough evidence regarding the efficacy of the in placebo) and in the sensory ulnar nerve tral or the peripheral nervous systems.1 majority of these emerging treatments for NP. (+2.9 m/sec in LAC vs. +0,1 m/sec in place- Peripheral NP is the result of small fibers dys- Nevertheless, the paucity of randomized con- bo).14 function or lesions seen in polyneuropathies trolled trials (RCTs) and clinical evidence does (diabetes, chronic alcohol abuse, infections, not mean that we should abandon these new chemotherapy, amyloidosis, etc.). Other fre- modalities. Instead, new studies are demanded quent causes include trigeminal neuralgia, to prove their efficacy.10,11 Alpha-lipoic-acid herpes zoster, complex regional pain syndrome (CRPS), entrapment syndromes, and others.2 ALA is known for its antioxidant properties [page 36] [Neurology International 2016; 8:6322] Review and its role in mitochondrial dehydrogenase part of the routine treatment of NP. Despite a reactions. ALA has demonstrated protection Selective angiotensin II type 2- lack of convincing RCTs addressing the effica- against oxidative stress in models of ischemia- receptor antagonist: EMA401 cy of these new therapies, there is a need for reperfusion lesion, diabetes, neurodegenera- further studies. With advancing knowledge on the pathophysiology of pain, new methods tion, HIV activation and others. Recent studies This class of drug is considered a new alter- might be proposed, ensuring greater effective- suggest that ALA plays a much broader role native for NP. EMA401 is a selective angiotensin 15,16 ness of different therapies, with a lower per- than just simply being an antioxidant. II type 2-receptor antagonist. In a randomized, centage of patients with refractory pain. Doing A multicenter, randomized, double-blind, controlled, double blind, clinical trial 181 so, a new paradigm for the treatment of chron- placebo-controlled trial with 181 diabetic patients received 100 mg EMA401 twice daily or ic pain will result. Despite the existence of sev- patients tested daily dose of 600 mg, 1200 mg, a placebo.25 The researchers found significantly eral studies for the relief of NP, pain control and 1800 mg of oral ALA, or placebo for NP. A less pain, after a week, compared with baseline continues being a challenge real pain reducing response with fewer side values in the EMA401 group, compared to the effects was found with the 600mg dose. placebo group, leading to a new possibility of References Furthermore, thioctic acid has a functional treatment for refractory NP.25 structure very similar to ALA and can be expected to have similar benefits to that of 1. Treede RD, Jensen TS, Campbell JN, et al. ALA.17,18 Neuropathic pain: redefinition and a grad- Cebranopadol ing system for clinical and research pur- poses. Neurology 2008;70:1630-5. 2. Dworkin RH, Backonja M, Rowbotham MC, This agent is an analgesic nociceptin/ et al. Advances in neuropathic pain: diag- Cannabinoids products orphanin FQ peptide (NOP) as well as an opi- nosis, mechanisms, and treatment recom- oid receptor agonist. It has high antinocicep- mendations. Arch Neurol 2003;60:1524-34. In a randomized trial using smoked tive and anti-hypersensitive effects without 3. Jensen TS, Baron R. Translation of symp- cannabis for chronic NP, the authors selected causing respiratory and motor side effects. In toms and signs into mechanisms in neuro- 23 patients. They concluded that a single many rat models of acute and chronic pain onlypathic pain. Pain 2003;102:1-8. inhalation of 25 mg of 9.4% tetrahydrocannabi- (tail-flick, rheumatoid arthritis, bone cancer, 4. Woolf CJ, Mannion RJ. Neuropathic pain: nol herbal cannabis three times daily for five spinal nerve ligation, diabetic neuropathy) its aetiology, symptoms, mechanisms, and days may cause pain relief, improve the quality results have been proven positive for amelio- management. Lancet 1999;353:1959-64. of sleep and is well tolerated.19,20 rating NP.26 In spite of this, other studies are use 5. Schug SA, Goddard C. Recent advances in In another study, patients with MS were necessary before the usage in humans the pharmacological management of acute tested by using an oral spray with 2.7 mg of becomes possible. and chronic pain. Ann Palliat Med tetrahydrocannabinol and 2.5 of delta-9- 2014;3:263-75.
Recommended publications
  • VOLUME 7 2 . No. 4 . AUGUST 2 0
    VOLUME 72 . No.4 . AUGUST 2020 © 2020 EDIZIONI MINERVA MEDICA Minerva Pediatrica 2020 August;72(4):288-311 Online version at http://www.minervamedica.it DOI: 10.23736/S0026-4946.20.05861-2 REVIEW MANAGEMENT OF THE MAIN ENDOCRINE AND DIABETIC DISORDERS IN CHILDREN Current treatment for polycystic ovary syndrome: focus on adolescence Maria E. STREET 1 *, Francesca CIRILLO 1, Cecilia CATELLANI 1, 2, Marco DAURIZ 3, 4, Pietro LAZZERONI 1, Chiara SARTORI 1, Paolo MOGHETTI 4 1Division of Pediatric Endocrinology and Diabetology, Department of Mother and Child, Azienda USL – IRCCS di Reggio Emilia, Reggio Emilia, Italy; 2Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy; 3Section of Endocrinology and Diabetes, Department of Internal Medicine, Bolzano General Hospital, Bolzano, Italy; 4Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Hospital Trust of Verona, Verona, Italy *Corresponding author: Maria E. Street, Division of Pediatric Endocrinology and Diabetology, Department of Mother and Child, Azienda USL – IRCCS di Reggio Emilia, Viale Risorgimento 80, 42123 Reggio Emilia, Italy. E-mail: [email protected] ABSTRACT Polycystic ovary syndrome (PCOS) is the most frequent endocrine disorder in women and it is associated with an in- creased rate of infertility. Its etiology remains largely unknown, although both genetic and environmental factors play a role. PCOS is characterized by insulin resistance, metabolic disorders and low-grade chronic inflammation. To date, the treatment of PCOS is mainly symptomatic and aimed at reducing clinical signs of hyperandrogenism (hirsutism and acne), at improving menstrual cyclicity and at favoring ovulation. Since PCOS pathophysiology is still largely unknown, the therapeutic interventions currently in place are rarely cause-specific.
    [Show full text]
  • Biased Versus Partial Agonism in the Search for Safer Opioid Analgesics
    molecules Review Biased versus Partial Agonism in the Search for Safer Opioid Analgesics Joaquim Azevedo Neto 1 , Anna Costanzini 2 , Roberto De Giorgio 2 , David G. Lambert 3 , Chiara Ruzza 1,4,* and Girolamo Calò 1 1 Department of Biomedical and Specialty Surgical Sciences, Section of Pharmacology, University of Ferrara, 44121 Ferrara, Italy; [email protected] (J.A.N.); [email protected] (G.C.) 2 Department of Morphology, Surgery, Experimental Medicine, University of Ferrara, 44121 Ferrara, Italy; [email protected] (A.C.); [email protected] (R.D.G.) 3 Department of Cardiovascular Sciences, Anesthesia, Critical Care and Pain Management, University of Leicester, Leicester LE1 7RH, UK; [email protected] 4 Technopole of Ferrara, LTTA Laboratory for Advanced Therapies, 44122 Ferrara, Italy * Correspondence: [email protected] Academic Editor: Helmut Schmidhammer Received: 23 July 2020; Accepted: 23 August 2020; Published: 25 August 2020 Abstract: Opioids such as morphine—acting at the mu opioid receptor—are the mainstay for treatment of moderate to severe pain and have good efficacy in these indications. However, these drugs produce a plethora of unwanted adverse effects including respiratory depression, constipation, immune suppression and with prolonged treatment, tolerance, dependence and abuse liability. Studies in β-arrestin 2 gene knockout (βarr2( / )) animals indicate that morphine analgesia is potentiated − − while side effects are reduced, suggesting that drugs biased away from arrestin may manifest with a reduced-side-effect profile. However, there is controversy in this area with improvement of morphine-induced constipation and reduced respiratory effects in βarr2( / ) mice. Moreover, − − studies performed with mice genetically engineered with G-protein-biased mu receptors suggested increased sensitivity of these animals to both analgesic actions and side effects of opioid drugs.
    [Show full text]
  • Summary Analgesics Dec2019
    Status as of December 31, 2019 UPDATE STATUS: N = New, A = Advanced, C = Changed, S = Same (No Change), D = Discontinued Update Emerging treatments for acute and chronic pain Development Status, Route, Contact information Status Agent Description / Mechanism of Opioid Function / Target Indication / Other Comments Sponsor / Originator Status Route URL Action (Y/No) 2019 UPDATES / CONTINUING PRODUCTS FROM 2018 Small molecule, inhibition of 1% diacerein TWi Biotechnology / caspase-1, block activation of 1 (AC-203 / caspase-1 inhibitor Inherited Epidermolysis Bullosa Castle Creek Phase 2 No Topical www.twibiotech.com NLRP3 inflamasomes; reduced CCP-020) Pharmaceuticals IL-1beta and IL-18 Small molecule; topical NSAID Frontier 2 AB001 NSAID formulation (nondisclosed active Chronic low back pain Phase 2 No Topical www.frontierbiotech.com/en/products/1.html Biotechnologies ingredient) Small molecule; oral uricosuric / anti-inflammatory agent + febuxostat (xanthine oxidase Gout in patients taking urate- Uricosuric + 3 AC-201 CR inhibitor); inhibition of NLRP3 lowering therapy; Gout; TWi Biotechnology Phase 2 No Oral www.twibiotech.com/rAndD_11 xanthine oxidase inflammasome assembly, reduced Epidermolysis Bullosa Simplex (EBS) production of caspase-1 and cytokine IL-1Beta www.arraybiopharma.com/our-science/our-pipeline AK-1830 Small molecule; tropomyosin Array BioPharma / 4 TrkA Pain, inflammation Phase 1 No Oral www.asahi- A (ARRY-954) receptor kinase A (TrkA) inhibitor Asahi Kasei Pharma kasei.co.jp/asahi/en/news/2016/e160401_2.html www.neurosmedical.com/clinical-research;
    [Show full text]
  • An Open-Label Pilot Trial of Alpha-Lipoic Acid for Weight Loss in Patients with Schizophrenia Without Diabetes Joseph C
    Case Reports An Open-Label Pilot Trial of Alpha-Lipoic Acid for Weight Loss in Patients with Schizophrenia without Diabetes Joseph C. Ratliff1 , Laura B. Palmese 1, Erin L. Reutenauer 1, Cenk Tek 1 Abstract A possible mechanism of antipsychotic-induced weight gain is activation of hypothalamic monophosphate-dependent kinase (AMPK) mediated by histamine 1 receptors. Alpha-lipoic acid (ALA), a potent antioxidant, counteracts this ef- fect and may be helpful in reducing weight for patients taking antipsychotics. The objective of this open-label study was to assess the efficacy of ALA (1,200 mg) on twelve non-diabetic schizophrenia patients over ten weeks. Participants lost significant weight during the intervention (-2.2 kg±2.5 kg). ALA was well tolerated and was particularly effective for individuals taking strongly antihistaminic antipsychotics (-2.9 kg±2.6 kg vs. -0.5 kg±1.0 kg). Clinical Trial Registra- tion: NCT01355952. Key Words: Schizophrenia, Obesity, Schizoaffective Disorder, Alpha-Lipoic Acid Introduction dependent protein kinase (AMPK) in the hypothalamus Antipsychotic medications appear to induce weight (4). In the periphery, AMPK increases energy utilization; gain, which results in increased rates of obesity in schizo- AMPK activity in the hypothalamus increases appetite. phrenia (1). Schizophrenia patients have significantly short- Several highly orexigenic (stimulates appetite) antipsy- er life expectancy than the general population (2); most of chotics such as clozapine, olanzapine, and quetiapine are this excess mortality is attributed to diabetes and cardiovas- shown to activate AMPK in the hypothalamus in animal cular disease (3); weight gain is a significant contributor to studies whereas other antipsychotic medications do not (4).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0236506 A1 SCHWARTZ Et Al
    US 2011 0236506A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0236506 A1 SCHWARTZ et al. (43) Pub. Date: Sep. 29, 2011 (54) PHARMACEUTICAL ASSOCIATION Publication Classification CONTAINING LIPOCACID AND (51) Int. Cl. HYDROXYCTRIC ACIDAS ACTIVE A633/24 (2006.01) INGREDIENTS A63L/385 (2006.01) A63/685 (2006.01) (75) Inventors: Laurent SCHWARTZ, Paris (FR): A63/4985 (2006.01) Adeline GUAIS-VERGNE, A63L/7056 (2006.01) Draveil (FR) A6IP35/00 (2006.01) (73) Assignees: Laurent SCHWARTZ, Paris (FR): (52) U.S. Cl. ........... 424/649; 514/440; 514/77: 514/249; BIOREBUS, Paris (FR) 514/52 (21) Appl. No.: 13/099,897 (57) ABSTRACT Pharmaceutical combination containing lipoic acid and (22) Filed: May 3, 2011 hydroxycitric acid as active ingredients. The present inven tion relates to a novel pharmaceutical combination and to the Related U.S. Application Data use thereof for producing a medicament having an antitumor (63) Continuation of application No. PCT/FR2009/ activity. According to the invention, this combination com 052110, filed on Nov. 2, 2009. prises, as active ingredients: lipoic acid or one of the pharma ceutically acceptable salts thereof, and hydroxycitric acid or (30) Foreign Application Priority Data one of the pharmaceutically acceptable salts thereof. Said active ingredients being formulated together or separately for Nov. 3, 2008 (FR) ....................................... O8574.48 a conjugated, simultaneous or separate use. Patent Application Publication Sep. 29, 2011 Sheet 1 of 9 US 2011/023650.6 A1 lipoic acid alone -29 f2 f Niger of ces i{t} v s 6 g i w 4. 6 8 i 2 Concentrations tumoi.i.
    [Show full text]
  • Philadelphia
    Saturday, April 18th, 2015 PCOS Awareness Symposium 2015 Philadelphia Polycystic Ovary Syndrome: Creating a Treatment Plan Katherine Sherif, MD Professor & Vice Chair, Department of Medicine Director, Jefferson Women’s Primary Care Thomas Jefferson University The Canary in the Coalmine . PCOS seems to accelerate the aging process . It is possible to reverse the aging process . Be scrupulous in your commitment to be healthy Multiple Systems . Reproductive . Endocrinologic . Cardiac . Renal (kidney) . Hepatic (liver) . Brain (mood) . Dermatologic Multiple Signs & Symptoms Irregular periods, Bleeding too much, Bleeding too little, Anxiety, Depression, Eating disorders, Weight gain, Acanthosis nigricans, Skin tags, Follicular keratitis, Hirsutism, Acne, Alopecia, Excess sweating, Seborrheic dermatitis, Hidradenitis supparativa, Fatty liver, High triglycerides, low HDL-cholesterol, Elevated glucose, Infertility, Breastfeeding problems, Poor sleep, Miscarriages, Fatigue, Endometrial cancer Multiple Pathways GnRH pulsatility Theca cell LH Progesterone 17 - OH P testosterone estrone androstenedione & TGranulosa A* Estradiol X Follicle Peripheral conversion A* = aromatase More Pathways! GnRH Insulin pulsatility Theca cell LH Progesterone 17 - OH P testosterone estrone androstenedione testosterone estradiol X ↓ SHBG Free T X Follicle Peripheral conversion The Magic Bullet The oral contraceptive pill . High doses of estrogen (ethinyl estradiol) . Increase SHBG and lower free testosterone* . Improve skin symptoms in most: . Alopecia .
    [Show full text]
  • The Main Tea Eta a El Mattitauli Mali Malta
    THE MAIN TEA ETA USA 20180169172A1EL MATTITAULI MALI MALTA ( 19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2018 /0169172 A1 Kariman (43 ) Pub . Date : Jun . 21 , 2018 ( 54 ) COMPOUND AND METHOD FOR A61K 31/ 437 ( 2006 .01 ) REDUCING APPETITE , FATIGUE AND PAIN A61K 9 / 48 (2006 .01 ) (52 ) U . S . CI. (71 ) Applicant : Alexander Kariman , Rockville , MD CPC . .. .. .. .. A61K 36 / 74 (2013 .01 ) ; A61K 9 / 4825 (US ) (2013 . 01 ) ; A61K 31/ 437 ( 2013 . 01 ) ; A61K ( 72 ) Inventor: Alexander Kariman , Rockville , MD 31/ 4375 (2013 .01 ) (US ) ( 57 ) ABSTRACT The disclosed invention generally relates to pharmaceutical (21 ) Appl . No. : 15 /898 , 232 and nutraceutical compounds and methods for reducing appetite , muscle fatigue and spasticity , enhancing athletic ( 22 ) Filed : Feb . 16 , 2018 performance , and treating pain associated with cancer, trauma , medical procedure , and neurological diseases and Publication Classification disorders in subjects in need thereof. The disclosed inven ( 51 ) Int. Ci. tion further relates to Kratom compounds where said com A61K 36 / 74 ( 2006 .01 ) pound contains at least some pharmacologically inactive A61K 31/ 4375 ( 2006 .01 ) component. pronuPatent Applicationolan Publication manu saJun . decor21, 2018 deSheet les 1 of 5 US 2018 /0169172 A1 reta Mitragynine 7 -OM - nitragynine *** * *momoda W . 00 . Paynantheine Speciogynine **** * * * ! 1000 co Speclociliatine Corynartheidine Figure 1 Patent Application Publication Jun . 21, 2018 Sheet 2 of 5 US 2018 /0169172 A1
    [Show full text]
  • Opioid Crisis—An Emphasis on Fentanyl Analogs
    brain sciences Editorial Opioid Crisis—An Emphasis on Fentanyl Analogs Kabirullah Lutfy College of Pharmacy, Western University of Health Sciences, Pomona, CA 91766, USA; [email protected] Received: 21 July 2020; Accepted: 23 July 2020; Published: 27 July 2020 Abstract: Opioids are the mainstay for the management of moderate to severe pain. However, their acute use is associated with several side effects, ranging from nausea, itching, sedation, hypotension to respiratory depression, and death. Also, chronic use of these drugs can lead to the development of tolerance, dependence, and eventually addiction. The most serious side effect, lethality due to opioid-induced overdose, has reached the level of national emergency, i.e., the opioid crisis, which is now the forefront of medicine. In a detailed review (Novel Synthetic Opioids: The Pathologist’s Point of View), Frisoni and colleagues have discussed the side effects of novel licit and illicit fentanyl derivatives, as well as the related compounds which are more potent and faster acting than morphine and other conventional opioids (Frisoni, et al., 2018). These drugs affect the central nervous system (CNS) and can promote the development of addiction due to the quick rush they induce because of their faster entry into the brain. These drugs also arrest the cardiovascular and pulmonary systems, increasing the chance of respiratory arrest, leading to opioid-induced overdose morbidity and mortality. The respiratory arrest induced by opioids can be potentiated by other CNS depressants, such as alcohol or benzodiazepines, and therefore may occur more frequently in polydrug users. Therefore, the use of these newer fentanyl derivatives as well as other fast acting opioids should be avoided or limited to specific cases and must be kept out of the reach of children and adolescents who are more vulnerable to become addicted or overdose themselves.
    [Show full text]
  • Datasheet Inhibitors / Agonists / Screening Libraries a DRUG SCREENING EXPERT
    Datasheet Inhibitors / Agonists / Screening Libraries A DRUG SCREENING EXPERT Product Name : Cebranopadol Catalog Number : T5167 CAS Number : 863513-91-1 Molecular Formula : C24H27FN2O Molecular Weight : 378.48 Description: Cebranopadol is an analgesic NOP and opioid receptor agonist with Kis of 0.9 nM, 0.7 nM, 2.6 nM, 18 nM for human NOP, μ-opioid (MOP), κ-opioid (KOP) and δ-opioid (DOP) receptor, respectively. Storage: 2 years -80°C in solvent; 3 years -20°C powder; DMSO 6 mg/mL Solubility Water Insoluble ( < 1 mg/ml refers to the product slightly soluble or insoluble ) NOP 13 nM (EC50, cell free) μ-opioid receptor 1.2 nM (EC50, cell free) Receptor (IC50) κ-opioid receptor 17 nM (EC50, cell free) δ-opioid receptor 110 nM (EC50, cell free) In vitro Activity Cebranopadol showed full agonistic efficacy at the human MOP and DOP receptors, almost full efficacy at the human NOP receptor, and partial efficacy at the human KOP receptor. In a functional [35S]GTPgS binding assay with membranes expressing the human 5-HT5A receptor, cebranopadol did not show agonistic or signirficant antagonistic effects at concentrations up to 10.0 μM [1]. In vivo Activity Cebranopadol exhibits highly potent and efficacious antinociceptive and antihypersensitive effects in several rat models of acute and chronic pain with ED50 values of 0.5-5.6 μg/kg after intravenous and 25.1 μg/kg after oral administration. Cebranopadol's duration of action is long (up to 7 hours after intravenous 12 μg/kg; >9 hours after oral 55 μg/kg in the rat tail-flick test) [1].
    [Show full text]
  • Mitochondrial Dysfunction and Chronic Inflammation in Polycystic
    International Journal of Molecular Sciences Review Mitochondrial Dysfunction and Chronic Inflammation in Polycystic Ovary Syndrome Siarhei A. Dabravolski 1,*, Nikita G. Nikiforov 2,3,4, Ali H. Eid 5,6,7, Ludmila V. Nedosugova 8, Antonina V. Starodubova 9,10, Tatyana V. Popkova 11, Evgeny E. Bezsonov 4,12 and Alexander N. Orekhov 4 1 Department of Clinical Diagnostics, Vitebsk State Academy of Veterinary Medicine [UO VGAVM], 7/11 Dovatora Str., 210026 Vitebsk, Belarus 2 Center of Collective Usage, Institute of Gene Biology, Russian Academy of Sciences, 34/5 Vavilova Street, 119334 Moscow, Russia; [email protected] 3 Laboratory of Medical Genetics, Institute of Experimental Cardiology, National Medical Research Center of Cardiology, 121552 Moscow, Russia 4 Laboratory of Cellular and Molecular Pathology of Cardiovascular System, Institute of Human Morphology, 3 Tsyurupa Street, 117418 Moscow, Russia; [email protected] (E.E.B.); [email protected] (A.N.O.) 5 Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, Doha 2713, Qatar; [email protected] 6 Biomedical and Pharmaceutical Research Unit, QU Health, Qatar University, Doha 2713, Qatar 7 Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon 8 Citation: Dabravolski, S.A.; Federal State Autonomous Educational Institution of Higher Education, I. M. Sechenov First Moscow State Nikiforov, N.G.; Eid, A.H.; Medical University (Sechenov University), 8/2 Trubenskaya Street, 119991 Moscow, Russia; [email protected] 9 Federal Research Centre for Nutrition, Biotechnology and Food Safety, 2/14 Ustinsky Passage, Nedosugova, L.V.; Starodubova, A.V.; 109240 Moscow, Russia; [email protected] Popkova, T.V.; Bezsonov, E.E.; 10 Pirogov Russian National Research Medical University, 1 Ostrovitianov Street, 117997 Moscow, Russia Orekhov, A.N.
    [Show full text]
  • Safety of Alpha-Lipoic Acid Use in Food Supplements
    DTU Doc nr. 17/14450 Date 10.10.2017 Safety of alpha-lipoic acid use in food supplements The Danish Veterinary and Food Administration has asked DTU FOOD to assess the safety of alpha-lipoic acid use in food supplements in a recommended daily dose of 150-200 mg per day. Specification for alpha-lipoic acid SYNONYMS Thioctic acid 1,2-dithiolane-3-pentanoic acid; 1,2-dithiolane-3-valeric acid DEFINITION Chemical name 1,2-Dithiolan-3-pentanic acid CAS Number 1077-28-7 Chemical formula Molecular formula C8H14O2S2 Molecular weight 206.32 g/mol Content Not less than 99.0% and no more than 101.0% alpha-lipoic acid determined by gas chromatography IDENTIFICATION Identification test IR absorption. The spectrum should be in accordance with an equivalent reference spectrum 60-62° C A. Melting point 22 ° B. Specific rotation [α]D : +/- 1.0 (50 mg/ml in ethanol) PURITY Loss on drying No more than 0,2% Ashes No more than 0.1% Heavy metals No more than 10 mg/kg (by method II, Ph. US 39., 673. Mercury is not identified by this test) Lead Not more than 1 mg/kg Specification in accordance with the United States Pharmacopeia (USP) Studies in humans No studies on alpha-lipoic acid conducted in healthy subjects were identified in the literature. Healthy subjects are the target group for food supplements. Several studies conducted in different patient groups including patients with diabetic neuropathy, infertile men, overweight or obese hypertensive, diabetic or hypercholesterolemic subjects were identified (Han et al., 2012; Koh et al., 2011 ; Hahm et al., 2004; Technical University of Denmark Kemitorvet Ph.
    [Show full text]
  • Treating Burning Mouth Syndrome Constance R
    East Tennessee State University Digital Commons @ East Tennessee State University ETSU Faculty Works Faculty Works 1-1-2009 Treating Burning Mouth Syndrome Constance R. Sharuga East Tennessee State University Debra Dotson East Tennessee State University Tabitha Price East Tennessee State University, [email protected] Follow this and additional works at: https://dc.etsu.edu/etsu-works Part of the Dental Hygiene Commons Citation Information Sharuga, Constance R.; Dotson, Debra; and Price, Tabitha. 2009. Treating Burning Mouth Syndrome. Dimensions of Dental Hygiene. Vol.7(12). 36-39. http://www.dimensionsofdentalhygiene.com/2009/12_December/Features/ Treating_Burning_Mouth_Syndrome.aspx ISSN: 1542-7919 This Article is brought to you for free and open access by the Faculty Works at Digital Commons @ East Tennessee State University. It has been accepted for inclusion in ETSU Faculty Works by an authorized administrator of Digital Commons @ East Tennessee State University. For more information, please contact [email protected]. Treating Burning Mouth Syndrome Copyright Statement Reprinted with permission. Constance R. Sharuga, Deborah Dotson, and Tabitha Price. Treating burning mouth syndrome. Dimensions of Dental Hygiene, December 2009; 7(12):36-39. This article is available at Digital Commons @ East Tennessee State University: https://dc.etsu.edu/etsu-works/2529 7/16/2018 Dimensions of Dental Hygiene Burning mouth syndrome (BMS) is a chronic, painful condition with no clear etiology or specific, proven treatment. BMS is also known as burning tongue syndrome, glossodynia, glossopyrosis, stomatodynia, stomatopyrosis, and oral dysesthesia.1,2 The syndrome is characterized by burning and/or painful sensations of the mouth, usually in the absence of clinical or laboratory findings.3 It can occur anywhere in the mouth.
    [Show full text]